OCS earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -5.38. Updated 2026-07-23.
Oculis Holding (OCS) Research Hub
Oculis Holding (OCS) trades on NASDAQ, CH in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 10.56 USD (-7.93%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -5.38, market cap 0.66B. This hub links to the full technical, earnings and options research available for OCS.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, CH |
| Last close | 10.56 USD (-7.93%) |
| 52-week range | 10.5 USD – 14.35 USD |
| Trend regime | Range |
| 14-day RSI | 23 (Oversold) |
| Trailing P/E | -5.38 |
| Market cap | 0.66B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for OCS
Covered Call on OCS: how it works, illustrative setup around the real 10.56 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on OCS: how it works, illustrative setup around the real 10.56 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on OCS: how it works, illustrative setup around the real 10.56 USD price, max profit/loss, breakeven and when to use it. Educational.
OCS technical analysis: range, last 10.56 USD, RSI 23, 52w range 10.5 USD–14.35 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is OCS in?
Oculis Holding (OCS) is classified under Healthcare (Biotechnology), listed on NASDAQ, CH.
Is OCS in an uptrend or downtrend?
As of 2026-09-11, OCS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is OCS's trailing P/E ratio?
OCS's trailing P/E is -5.38, with a market cap of 0.66B. See the earnings research page for full valuation detail.
When does OCS next report earnings?
OCS is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -0.48 USD.